Tag: Eye Disease

FDA Panel Voted in Favor of Horizon Experimental Treatment for Active Thyroid Eye Disease

Independent advisers to the U.S. Food and Drug Administration voted unanimously in favor of Horizon Therapeutics Plc’s experimental treatment for active thyroid eye disease, taking the drug closer tow...

FDA Approved First Contact Lens Indicated to Slow Myopia Progression

The U.S. Food and Drug Administration approved the first contact lens indicated to slow the progression of myopia (nearsightedness) in children between the ages of 8 and 12 years old at the initiation...

Sun Pharma Commercialized CEQUA in the U.S.

sun pharma
Sun Pharmaceutical Industries Ltd. announced that one of its wholly-owned subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S. CEQUA, which offers the highest con...

Allergan Expands REFRESH® Portfolio

Allergan plc, a leading global pharmaceutical company with a more than 70-year heritage in eye care, announced the launch of three new over-the-counter (OTC)  REFRESH® RELIEVA™ products: REFRESH® RELI...

Alcon Launched Production of Intraocular Cataract Lenses in Russia

glaucoma
Alkon, the world leader in ophthalmology, announced the launch in production of intraocular cataract lenses in Russia. The localization project is being implemented jointly with the NanOptika company,...

FDA Granted Fast Review Status for Horizon Therapeutics’ Teprotumumab

glaucoma
The FDA has granted a fast review for Horizon Therapeutics’ teprotumumab for active thyroid eye disease (TED), a rare vision-threatening autoimmune condition. After accepting Horizon’s filing, the ...

Teprotumumab Expanded Access Program Announced by Horizon Therapeutics

glaucoma
Horizon Therapeutics announced the availability of an expanded access program for its investigational medicine teprotumumab. Developed in partnership with the U.S. Food and Drug Administration (FDA...

Novartis Division Acquire US PowerVision

Acquisition demonstrates Alcon's commitment to driving growth and innovation in advanced technology intraocular lenses (AT-IOLS) to meet the needs of cataract surgery patients who desire spectacle ind...

FDA Accepted NDA from Kala for Dry Eye Disease Drug

The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) submitted by Kala Pharmaceuticals for its KPI-121 0.25% product candidate. The FDA will review the NDA for KPI-12...